StockpollyBeta
Get App
Delisting riskPopularity #4,507
CVM · AMEX · Biotechnology

CEL-SCI (CVM)

Develops a pre-surgical cytokine treatment for selected head-and-neck cancer patients.

$1.72
vs last close+0.02 (+1.04%)

In millions of USD, except per-share figures

In millionsQ4 FY23Sep 2023Q1 FY24Dec 2023Q2 FY24Mar 2024Q3 FY24Jun 2024Q4 FY24Sep 2024Q1 FY25Dec 2024Q2 FY25Mar 2025Q3 FY25Jun 2025Q4 FY25Sep 2025Q1 FY26Dec 2025Q2 FY26Mar 2026Q3 FY26Jun 2026
Cost of revenue101011411411
Gross profit−10−10−1−1−4−1−1−4−1−1
666756255245
Research & development545544444444
121212221221
Selling & marketing00−1000000000
General & administrative022202220220
Other expenses00000−1−4−10−4−10
Operating income−7−6−7−7−6−7−6−5−6−5−5−6
000000000000
Interest expense000000000000
Other non-operating income000000000000
Income before tax−8−7−7−7−6−7−7−6−6−5−5−6
Net income from continuing operations−8−7−7−7−6−7−7−6−6−5−5−6
Net income−8−7−7−7−6−7−7−6−6−5−5−6
EPS, basic−$4.87−$0.14−$4.20−$4.18−$3.07−$3.25−$2.33−$1.36−$0.76−$0.68−$0.67−$0.47
EPS, diluted−$4.87−$0.14−$4.20−$4.18−$3.07−$3.25−$2.33−$1.36−$0.76−$0.68−$0.67−$0.47
Weighted average shares, basic24822223488812
Weighted average shares, diluted24822223488812
EBITDA−6−6−6−6−5−6−5−5−5−4−4−5
Depreciation & amortization111111111111
EBIT−7−7−7−7−6−7−6−5−6−5−5−6